XML 41 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Geographic and Segment Information
12 Months Ended
Dec. 31, 2024
Geographic and Segment Information  
Geographic and Segment Information

16.  Geographic and Segment Information

Geographic information for the years ended December 31, 2024 and 2023 is as follows (in thousands):

 

Year Ended December 31, 

    

2024

    

2023

Revenue

 

  

 

  

United Kingdom

$

43

$

420

Total Revenue

$

43

$

420

Net loss

 

  

 

  

United States

$

(37)

$

(808)

United Kingdom

 

(11,175)

 

(21,747)

Total Net Loss

$

(11,212)

$

(22,555)

 

December 31, 

    

2024

    

2023

Total Assets

 

  

 

  

United States

$

3,285

$

2,938

United Kingdom

 

809

 

5,867

Total Assets

$

4,094

$

8,805

Long Lived Assets, net

 

  

 

  

United States

$

1

$

United Kingdom

 

2

 

9

Total Long Lived Assets, net

$

3

$

9

The Company operates as a single segment engaged in the development of innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. Consistent with our operational structure, our Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Managing and allocating resources at the consolidated level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a geographic or some other basis. Consistent with this decision-making process, our CEO considers consolidated net loss, which is our single segment’s principal measure of segment profit and loss, when evaluating performance and allocating company-wide resources.

Significant expenses are amounts that are regularly provided to our CEO and included in consolidated net loss, our primary measure of our single segment’s profit or loss. Our CEO regularly reviews reported consolidated revenues, significant expenses and consolidated net loss, in addition to forecasted revenues, significant expenses and net loss amounts for future periods.

A summary of our consolidated net loss for the years ended December 31, 2024 and 2023 is as follows, including the significant expenses provided to and regularly reviewed by our CEO:

 

December 31, 

    

2024

    

2023

Revenues

$

43

$

420

Operating expenses:

 

  

 

  

Research and development

 

6,655

 

19,155

General and administrative

 

5,392

 

6,718

Total operating expenses

 

12,047

 

25,873

Operating loss

 

(12,004)

 

(25,453)

Total other income (expense), net

 

10

 

(98)

Loss before taxes

 

(11,994)

 

(25,551)

Income tax benefit

 

782

2,996

Net loss

$

(11,212)

$

(22,555)